With AJ Bell and Embark confirming they are following Transact down the IPO trail and Nucleus reported to being thinking similarly, Tom Ellis looks at what lies behind the sudden bout of floatation fever sweeping the platform market.
Since Axa sold Elevate to Standard Life in May 2016 and Legal & General parted with Cofunds for a hefty fee in August 2016, little merger and acquisition (M&A) business has taken place in the adviser platform...
Four potential outcomes
Industry members abseil down Broadgate Tower
Hired as portfolio manager in global equity income team
'Three cycles are colliding'
Partner Insight: Alex Wright explains how he has honed his value contrarian approach to investing in the Fidelity Special Situations Fund and why the potential to lose money is often lower than in traditional funds